NCT01945710View on ClinicalTrials.gov

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

May 17, 2016

Conditions

Solid Tumors

Interventions

DRUG

Eribulin-LF

Trial Locations (4)

Unknown

Royal Marsden Hospital, Sutton

Beatson West of Scotland Cancer Centre, Glasgow

UCL Cancer Institute, London

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors

lead

Eisai Limited

INDUSTRY

NCT01945710 - An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter